Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.15    0.00 (0.00%)
Bid:
1.10
Ask:
1.20
Spread: 0.10 (9.091%)
Market Cap: £9.84m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

Chief Executive Officer Subscription

24 Aug 2022 07:00

RNS Number : 9905W
Tern PLC
24 August 2022
 

24 August 2022

 

Tern Plc

 

("Tern" or the "Company")

 

Chief Executive Officer Subscription

 

Tern Plc (AIM:TERN), the company focused on value creation from Internet of Things ("IoT") technology businesses, announces that on 23 August 2022, the Company entered into a direct subscription (the "Subscription") with Albert Sisto, Chief Executive Officer, via the Albert E Sisto Revocable Trust, for a total of 200,000 new Ordinary Shares of 0.02p pence each ("Ordinary Shares") at an issue price of 9.9p pence per share (the "Issue Price") (the "Subscription Shares").

 

The Subscription has been undertaken by the Company to allow Mr. Sisto to increase his interest in the Company, which is otherwise difficult for Mr. Sisto to do, due to his primary residency and tax status in the United States of America. The Issue Price is equal to the closing mid-market price of the Company's Ordinary Shares on AIM on the business day prior to this announcement.

 

Albert Sisto's total beneficial interest following this transaction will be 10,616,666 Ordinary Shares, representing approximately 3.01% of the voting rights in the Company's enlarged share capital following the issue of the Subscription Shares. The FCA notification, made in accordance with the requirements of the UK Market Abuse Regulation, is appended below.

 

Application has been made for the 200,000 Subscription Shares to be admitted to trading on AIM ("Admission"), which is expected to take place on or around 30 August 2022. Once issued, the Subscription Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

 

Total Voting Rights

 

Following Admission, the Company's issued ordinary share capital will consist of 352,214,701 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 352,214,701. With effect from Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries

 

 

Tern Plc

Al Sisto (CEO)

Sarah Payne (CFO)

via IFC Advisory

Allenby Capital Limited

(Nominated Adviser and Broker)

David Worlidge / Alex Brearley (Corporate Finance)

Matt Butlin / Kelly Gardiner (Sales and Corporate Broking)

Tel: 0203 328 5656

IFC Advisory

(Financial PR and IR)

Tim Metcalfe

Graham Herring

Florence Chandler

Tel: 0203 934 6630

tern@investor-focus.co.uk

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Albert Sisto

2.

Reason for the Notification

a)

Position/status

Director, Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tern plc

b)

LEI

2138005F87SODHL9CQ36

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary Shares of 0.02p each

Identification code

ISIN: GB00BFPMV798

 

b)

Nature of the transaction

Subscription of new ordinary shares

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.099 per share

200,000

d)

Aggregated information:

·Aggregated volume

·Price

 

200,000

£0.099 per share

e)

Date of the transaction

23 August 2022

f)

Place of the transaction

Outside a trading venue - conditional issue of new ordinary shares

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFSATAIVFIF
Date   Source Headline
9th Jul 20269:42 amRNSResult of GM
30th Jun 202610:49 amRNSResult of AGM
23rd Jun 20267:00 amRNSResults for the year ended 31 December 2025
8th Jun 20267:00 amRNSNotice of AGM
29th May 20265:00 pmRNSTotal Voting Rights
26th May 20267:00 amRNSInvestment in Talking Medicines CLNs
22nd May 20267:00 amRNSDevice Authority Convertible Loan Notes Investment
19th May 20267:00 amRNSPlacing to raise £222,000
12th May 20267:00 amRNS-RDevice Authority Strategic Partnership
8th May 202612:53 pmRNSResult of GM & Update on Open Offer
8th May 20267:00 amRNSResults of Open Offer
21st Apr 20267:00 amRNSOpen Offer and Notice of General Meeting
31st Mar 20265:00 pmRNSTotal Voting Rights
5th Mar 20267:00 amRNSExtension of loan facility agreement
3rd Mar 20267:00 amRNSResults of Open Offer
13th Feb 20267:00 amRNSOpen Offer at 0.40p to raise up to £384,408
5th Feb 20267:00 amRNS-RTern Notes Automotive Momentum at Device Authority
15th Jan 20267:00 amRNSUpdate regarding SVV2
8th Jan 20267:00 amRNSInvestor Presentations
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
12th Dec 20257:00 amRNSIssue of Talking Medicines Convertible Loan Notes
28th Nov 20257:00 amRNSUpdate regarding capital commitment to SVV2
25th Nov 20257:00 amRNSTalking Medicines CLN Modifications
31st Oct 20253:35 pmRNSTotal Voting Rights
15th Oct 20257:00 amRNSResults of Open Offer
9th Oct 20257:00 amRNSRemuneration Reductions & Distribution Commitment
29th Sep 20257:00 amRNSOpen Offer to raise up to £642,486
15th Sep 20257:00 amRNSExtension of Loan Facility Term
4th Sep 20257:00 amRNSInterim results for the six months to 30 June 2025
1st Sep 20257:00 amRNSAppointment of shareholder relations adviser
31st Jul 20254:34 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSResults of underwritten Open Offer & TVR
24th Jul 20257:00 amRNSReceipt of Bridging Loan
14th Jul 20257:00 amRNSUnderwritten Open Offer to raise £642,486
30th Jun 202512:07 pmRNSResult of AGM
13th Jun 20257:00 amRNSDirector Share Purchase
11th Jun 20257:00 amRNSDirector Share Purchase
6th Jun 20257:00 amRNSNotice of AGM and Director Retirement
5th Jun 20257:00 amRNSResults for the year ended 31 December 2024
30th May 20255:39 pmRNSTotal Voting Rights
7th May 20257:00 amRNSResults of Underwritten Open Offer
24th Apr 20257:00 amRNSPurple Transform appointment
17th Apr 20257:00 amRNSUnderwritten Open Offer to raise £340,140
11th Mar 20257:00 amRNS-RDevice Authority Microsoft & CyberArk Partnership
11th Mar 20257:00 amRNS-RSure Ventures Update
28th Feb 20255:00 pmRNSTotal Voting Rights
21st Feb 20257:00 amRNSPlacing to raise £221,154
14th Jan 20257:30 amRNS-RProgressive Equity Research Report
10th Jan 20257:00 amRNSInvestor Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.